Last10K.com

Alexion Pharmaceuticals, Inc. (ALXN) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

SEC Filings

Alexion Pharmaceuticals, Inc.

CIK: 899866 Ticker: ALXN




a2016earningsreleaseimagea15.jpg
Alexion Reports Fourth Quarter and Full Year 2018 Results

4Q18 total revenues of $1,128.8 million, a 24 percent increase over 4Q17 and a 30 percent volume increase

4Q18 GAAP diluted EPS of $(0.20); non-GAAP diluted EPS of $2.14

2019 guidance: revenue $4,625 to $4,700 million; GAAP diluted EPS of $6.14 to $7.26; non-GAAP diluted EPS of $9.10 to $9.30

SOLIRIS® (eculizumab) for Generalized Myasthenia Gravis (gMG) best Alexion launch in first year following regulatory approval

U.S. launch underway for ULTOMIRISTM (ravulizumab-cwvz) in adults with paroxysmal nocturnal hemoglobinuria (PNH); EU and Japanese applications under review

Filed U.S. and EU submissions for SOLIRIS in neuromyelitis optica spectrum disorder (NMOSD) and on track to file in Japan later in 2019

Announced collaboration with Caelum Biosciences

BOSTON, February 4, 2019- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2018. Total revenues for the full year of 2018 were $4,131.2 million, a 16 percent increase compared to 2017. The positive impact of foreign currency on total revenues year-over-year was less than one percent, or $5.9 million, inclusive of hedging activities. On a GAAP basis, diluted earnings per share (EPS) for the full year of 2018 was $0.35, an 82 percent decrease versus the prior year, inclusive of $1,183.0 million of expense related to the value of the in-process research and development assets acquired in 2018. Non-GAAP diluted EPS for the full year of 2018 was $7.92, a 35 percent increase versus the prior year.

Total revenues in the fourth quarter were $1,128.8 million, a 24 percent increase compared to the same period in 2017. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $5.5 million, inclusive of hedging activities. On a GAAP basis, diluted EPS in the quarter was $(0.20), a 254 percent decrease versus the prior year, inclusive of $379.3 million of expense related to the value of the in-process research and development asset acquired in connection with our acquisition of Syntimmune. Non-GAAP diluted EPS for the fourth quarter of 2018 was $2.14, a 45 percent increase versus the fourth quarter of 2017.

"2018 was a transformational year for Alexion. I am proud of our many accomplishments, including entering rare neurology and making SOLIRIS for gMG Alexion's best launch ever, completing the Phase 3 program and launching ULTOMIRIS for PNH in the U.S., delivering groundbreaking Phase 3 data and submitting regulatory filings for SOLIRIS in NMOSD and rebuilding our pipeline through disciplined business development, all while continuing to grow our base business," said Ludwig Hantson, Ph.D., Chief

1

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Monday, February 4, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alexion Pharmaceuticals, Inc..

Continue

Assess how Alexion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information Document
Consolidated Balance Sheets (Parenthetical)
Consolidated Balance Sheets Consolidated Balance Sheets
Consolidated Statement Of Comprehensive Income
Consolidated Statement Of Comprehensive Income (Parentheticals)
Consolidated Statements Of Operations
Statement Of Cash Flows
Statement Of Shareholders' Equity
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (Schedule Of Accrued Expenses) (Details)
Accrued Expenses (Tables)
Acquisitions
Acquisitions (Narrative) (Details)
Acquisitions (Summary Of Total Consideration) (Details)
Acquisitions (Tables)
Acquisitions Asset Acquisition (Details)
Acquisitions Syntimmune (Details)
Acquisitions Wilson Acquisition (Details)
Business Overview And Summary Of Significant Accounting Policies
Business Overview And Summary Of Significant Accounting Policies (Earnings Per Common Share) (Details)
Business Overview And Summary Of Significant Accounting Policies (Inventories) (Details)
Business Overview And Summary Of Significant Accounting Policies (Narrative) (Details)
Business Overview And Summary Of Significant Accounting Policies (Policies)
Business Overview And Summary Of Significant Accounting Policies (Tables)
Business Overview And Summary Of Significant Accounting Policies Business Overview (Details)
Commitments And Contingencies
Commitments And Contingencies (Narrative) (Details)
Commitments And Contingencies (Schedule Of Aggregate Future Minimum Annual Rental Payments) (Details)
Commitments And Contingencies (Tables)
Debt
Debt (Details)
Debt - Schedule Of Maturities Of Long-Term Debt (Details)
Debt Debt (Tables)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Narrative) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Offsetting Assets And Liabilities) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details)
Derivative Instruments And Hedging Activities (Tables)
Derivative Instruments And Hedging Activities Rev From Contract (Details)
Derivative Instruments And Hedging Activities Schedule Of Cash Flow Hedges In Aoci (Details)
Derivative Instruments And Hedging Activities Schedule Of Cash Flow Hedges In Aoci (Nine Months) (Details)
Derivative Instruments And Hedging Activities Schedule Of Interest Rate Derivatives (Details)
Derivative Instruments And Hedging Activities Schedule Of Interest Rate Derivatives (Tables)
Employee Benefit Plans
Employee Benefit Plans (Narrative) (Details)
Employee Benefit Plans (Schedule Of Change In Benefit Obligation) (Details)
Employee Benefit Plans (Schedule Of Change In Plan Assets) (Details)
Employee Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost) (Details)
Employee Benefit Plans (Schedule Of Estimated Future Benefit Payments) (Details)
Employee Benefit Plans (Schedule Of Fair Value Of Plan Assets) (Details)
Employee Benefit Plans (Schedule Of Other Changes In Plan Assets And Benefit Obligations Recognized In Other Comprehensive Income) (Details)
Employee Benefit Plans (Schedule Of Weighted Average Assumptions Used To Calculate Net Periodic Benefit Cost And The Actuarial Present Value Of Projected Benefit Obligations) (Details)
Employee Benefit Plans (Tables)
Facility Lease Obligations
Facility Lease Obligations (Details)
Facility Lease Obligations (Tables)
Facility Lease Obligations - Aggregate Future Minimum Non-Cancellable Commitments Under Facility Lease Obligation (Details)
Fair Value Measurement
Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)
Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details)
Fair Value Measurement (Tables)
Income Taxes
Income Taxes (Narrative) (Details)
Income Taxes (Reconciliation Of The Statutory U.S. Federal Income Tax Rate To Effective Income Tax Rate) (Details)
Income Taxes (Reconciliation Of Unrecognized Tax Benefits) (Details)
Income Taxes (Schedule Of Components Of Deferred Tax Assets And Liabilities) (Details)
Income Taxes (Schedule Of Components Of Income Tax Provision (Benefit)) (Details)
Income Taxes (Schedule Of Income Tax Provision (Benefit) On Income Before Income Taxes) (Details)
Income Taxes (Tables)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (Schedule Of Changes In The Carrying Amount Of Goodwill) (Details)
Intangible Assets And Goodwill (Schedule Of Intangible Assets And Goodwill) (Details)
Intangible Assets And Goodwill (Tables)
Intangible Assets And Goodwill Narratives (Details)
Marketable Securities
Marketable Securities (Available-For-Sale Debt Securities By Contractual Maturity) (Details)
Marketable Securities (Available-For-Sale Securities By Classification In Balance Sheet) (Details)
Marketable Securities (Narrative) (Details)
Marketable Securities (Summary Of Avaiable-For-Sale Securities Held) (Details)
Marketable Securities (Tables)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Notes)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Reclassifications Out Of Accumulated Other Comprehensive Income) (Details)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Schedule Of Accumulated Other Comprehensive Income (Loss)) (Details)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Tables)
Other Investments (Details)
Other Investments Moderna Investment (Details)
Property, Plant And Equipment, Net
Property, Plant And Equipment, Net (Details)
Property, Plant And Equipment, Net (Tables)
Quarterly Financial Information (Unaudited)
Quarterly Financial Information (Unaudited) (Details)
Quarterly Financial Information (Unaudited) (Tables)
Restructuring (Tables)
Restructuring And Related Expenses
Restructuring And Related Expenses (Details)
Restructuring And Related Expenses - Reconciliation Of Restructuring Reserve (Details)
Segment Information
Segment Information (Details)
Segment Information (Tables)
Segment Information - Net Product Sales (Details)
Share-Based Compensation
Share-Based Compensation (Narrative) (Details)
Share-Based Compensation (Schedule Of Components Of Allocated Share-Based Compensation Expense And Capitalization Of Share Based Compensation Expense) (Details)
Share-Based Compensation (Schedule Of Ranges Of Weighted Average Assumptions) (Details)
Share-Based Compensation (Schedule Of Status Of Non-Vested Restricted Stock) (Details)
Share-Based Compensation (Schedule Of Status Of Stock Option Plans) (Details)
Share-Based Compensation (Tables)
Stockholders' Equity
Stockholders' Equity (Details)
Subsequent Events
Subsequent Events (Details)
Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0000899866-19-000010
Submitted to the SEC: Wed Feb 06 2019 9:03:21 AM EST
Accepted by the SEC: Wed Feb 06 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/alxn/0000899866-19-000010.htm